Jian Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian Huang has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiu Yu
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 shared publications Yanli Wang
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
9 shared publicationsRan Chen
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 shared publicationsXian Zhao
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 shared publicationsHailong Zhang
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai 200025, China
3 shared publicationsRunhui Lu
Department of Biochemistry and Molecular Cell Biology & Department of Thoracic Surgery Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications
Latest Publications
- 17 October 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (46) , 5018-5034
Phosphorylation of IRS4 at YY111/112 promotes LUSC progression via PI3K/AKT pathway activation
- 17 October 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (46) , 5018-5034
Phosphorylation of IRS4 at YY111/112 promotes LUSC progression via PI3K/AKT pathway activation
- Open Access
- 20 May 2026
- Published by Springer Nature in Research Square
Phosphorylation of IRS4 at YY111/112 promotes LUSC progression via PI3K/AKT pathway activation
Lung squamous cell carcinoma (LUSC) lacks effective targeted therapies despite frequent hyperactivation of the PI3K/AKT pathway, and the contribution of adaptor proteins to this process remains poorly defined. Here, we identify Insulin Receptor Substrate 4 (IRS4) as a common substrate of Src kinase and the phosphatase RPTPα, and uncover a previously unrecognized, conserved phosphorylation site at YY111/112 within the IRS4 PH domain. Src-mediated phosphorylation at this site is essential for IRS4-driven proliferation, anchorage-independent growth, and invasiveness in LUSC cells. Mechanistically, phosphorylation at YY111/112 induces conformational rearrangements in IRS4 that enhance the recruitment of the p85β SH2 domain to the YXXM motif of IRS4, thereby promoting AKT activation without altering IRS4 protein stability or subcellular distribution. An IRS4-derived cell-permeable phosphopeptide containing pYY111/112 disrupts the Src–IRS4 interaction and significantly suppresses tumor growth in vivo in a YY111/112-dependent manner. Consistently, YY111/112 phosphorylation is markedly elevated in human LUSC tissues and correlates with advanced disease stages. Collectively, these findings define a Src–IRS4–PI3K/AKT signaling axis and identify YY111/112 as a critical regulatory site of IRS4 and a potential therapeutic vulnerability in LUSC
- 20 May 2026
- Published by Springer Nature in Research Square
Open AccessPhosphorylation of IRS4 at YY111/112 promotes LUSC progression via PI3K/AKT pathway activation
Lung squamous cell carcinoma (LUSC) lacks effective targeted therapies despite frequent hyperactivation of the PI3K/AKT pathway, and the contribution of adaptor proteins to this process remains poorly defined. Here, we identify Insulin Receptor Substrate 4 (IRS4) as a common substrate of Src kinase and the phosphatase RPTPα, and uncover a previously unrecognized, conserved phosphorylation site at YY111/112 within the IRS4 PH domain. Src-mediated phosphorylation at this site is essential for IRS4-driven proliferation, anchorage-independent growth, and invasiveness in LUSC cells. Mechanistically, phosphorylation at YY111/112 induces conformational rearrangements in IRS4 that enhance the recruitment of the p85β SH2 domain to the YXXM motif of IRS4, thereby promoting AKT activation without altering IRS4 protein stability or subcellular distribution. An IRS4-derived cell-permeable phosphopeptide containing pYY111/112 disrupts the Src–IRS4 interaction and significantly suppresses tumor growth in vivo in a YY111/112-dependent manner. Consistently, YY111/112 phosphorylation is markedly elevated in human LUSC tissues and correlates with advanced disease stages. Collectively, these findings define a Src–IRS4–PI3K/AKT signaling axis and identify YY111/112 as a critical regulatory site of IRS4 and a potential therapeutic vulnerability in LUSC
- Open Access
- 30 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Targeting the TRIM25–AGO2–miR-148b-5p–ABCC1 axis overcomes chemoresistance in non-small cell lung cancer
Despite significant advances in the treatment of non-small cell lung cancer (NSCLC), acquired resistance remains a major obstacle in advanced stages. Elucidating the molecular mechanisms underlying resistance is crucial for improving clinical outcomes, overcoming therapeutic limitations, and developing effective combination strategies. Here, we identify TRIM25 as a key driver of tumor progression and chemoresistance by promoting the destabilization of AGO2. Mechanistically, TRIM25 directly binds to AGO2 and induces its polyubiquitination, triggering proteasomal degradation. This process downregulates miR-148b-5p, a tumor-suppressive miRNA that post-transcriptionally represses ABCC1 to counteract chemoresistance. Knockdown of TRIM25 restores AGO2 stability by attenuating ubiquitination, thereby reinstating miR-148b-5p-mediated suppression of ABCC1. Functionally, the TRIM25–AGO2–miR-148b-5p–ABCC1 axis inhibits tumor growth and re-sensitizes NSCLC cells to chemotherapy. Notably, therapeutic delivery of miR-148b-5p mimics robustly suppresses NSCLC progression and overcomes chemoresistance in cell lines, xenografts, and patient-derived xenograft (PDX) models, highlighting its translational potential. Our study unveils a previously unrecognized regulatory axis governing chemoresistance in NSCLC, providing both mechanistic insights and novel therapeutic avenues to combat treatment resistance.
- 30 April 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessTargeting the TRIM25–AGO2–miR-148b-5p–ABCC1 axis overcomes chemoresistance in non-small cell lung cancer
Despite significant advances in the treatment of non-small cell lung cancer (NSCLC), acquired resistance remains a major obstacle in advanced stages. Elucidating the molecular mechanisms underlying resistance is crucial for improving clinical outcomes, overcoming therapeutic limitations, and developing effective combination strategies. Here, we identify TRIM25 as a key driver of tumor progression and chemoresistance by promoting the destabilization of AGO2. Mechanistically, TRIM25 directly binds to AGO2 and induces its polyubiquitination, triggering proteasomal degradation. This process downregulates miR-148b-5p, a tumor-suppressive miRNA that post-transcriptionally represses ABCC1 to counteract chemoresistance. Knockdown of TRIM25 restores AGO2 stability by attenuating ubiquitination, thereby reinstating miR-148b-5p-mediated suppression of ABCC1. Functionally, the TRIM25–AGO2–miR-148b-5p–ABCC1 axis inhibits tumor growth and re-sensitizes NSCLC cells to chemotherapy. Notably, therapeutic delivery of miR-148b-5p mimics robustly suppresses NSCLC progression and overcomes chemoresistance in cell lines, xenografts, and patient-derived xenograft (PDX) models, highlighting its translational potential. Our study unveils a previously unrecognized regulatory axis governing chemoresistance in NSCLC, providing both mechanistic insights and novel therapeutic avenues to combat treatment resistance.
- Open Access
- 7 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-21
PABPC1 SUMOylation enhances cell survival by promoting mitophagy through stabilizing U-rich mRNAs within stress granules
Stress granules (SGs) are cytoplasmic, membraneless organelles that modulate mRNA metabolism and cellular adaptation under stress, yet the mechanisms by which they regulate cancer cell survival remain unclear. Here, we identify Poly(A)-Binding Protein Cytoplasmic 1 (PABPC1), a core SG component, as stress-inducible SUMOylation target. Upon various stress conditions, SUMOylated PABPC1 promotes SG assembly and enhances cancer cell survival. Transcriptome-wide analysis reveals that SUMOylated PABPC1 selectively stabilizes mRNAs enriched in conserved U-rich elements. Mechanistically, SUMOylated PABPC1 interacts with RNA-binding protein TIA1 to form PABPC1–SUMO–TIA1 complex that recruits U-rich mRNAs into SGs, protecting them from degradation. This process facilitates the expression of U-rich genes, such as mitophagy-related genes FUNDC1, BNIP3L, thereby maintaining cellular homeostasis and promoting cell survival under adverse conditions. Our findings reveal that PABPC1 SUMOylation connects stress granule assembly with selective U-rich mRNA stabilization and mitophagy, promoting cancer cell stress adaptation.
- 7 August 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-21
Open AccessPABPC1 SUMOylation enhances cell survival by promoting mitophagy through stabilizing U-rich mRNAs within stress granules
Stress granules (SGs) are cytoplasmic, membraneless organelles that modulate mRNA metabolism and cellular adaptation under stress, yet the mechanisms by which they regulate cancer cell survival remain unclear. Here, we identify Poly(A)-Binding Protein Cytoplasmic 1 (PABPC1), a core SG component, as stress-inducible SUMOylation target. Upon various stress conditions, SUMOylated PABPC1 promotes SG assembly and enhances cancer cell survival. Transcriptome-wide analysis reveals that SUMOylated PABPC1 selectively stabilizes mRNAs enriched in conserved U-rich elements. Mechanistically, SUMOylated PABPC1 interacts with RNA-binding protein TIA1 to form PABPC1–SUMO–TIA1 complex that recruits U-rich mRNAs into SGs, protecting them from degradation. This process facilitates the expression of U-rich genes, such as mitophagy-related genes FUNDC1, BNIP3L, thereby maintaining cellular homeostasis and promoting cell survival under adverse conditions. Our findings reveal that PABPC1 SUMOylation connects stress granule assembly with selective U-rich mRNA stabilization and mitophagy, promoting cancer cell stress adaptation.
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
LHPP Attenuates Lipid Dysfunction of Uveal Melanoma by Relieving the Histidine Phosphorylation of ACO2
Histidine phosphorylation, the neglected but vital phosphoproteome, is a reversible posttranslational modification catalyzed by histidine kinases and erased by phosphohistidine (pHis) phosphatases (e.g., LHPP). Traditional types of phosphorylation have been implicated with the deadliest adult ocular tumor uveal melanoma (UM), which is lipid metabolism dysfunction related. However, the role of histidine phosphorylation in UM remains unknown. Here, up-regulated histidine phosphorylation is associated with poor UM prognosis. Reversal of histidine phosphorylation by LHPP exerts therapeutic effects. Mechanistically, we identified LHPP as metabolically related protein with mitochondrial targeting sequence. LHPP interacts and reduces excessive histidine phosphorylation of mitochondrial aconitase ACO2 at H73 site, thus restoring ACO2 enzymatic activity and mitochondrial citrate transit in TCA cycle. Reduction of citrate accumulation attenuates overloaded lipid synthesis. Besides, genetic ablation of LHPP in mouse eye exhibits abnormal lipid metabolism. These findings illustrate the antagonistic roles of oncogenic histidine phosphorylation and therapeutic mitochondrial LHPP and provide metabolic insight of pHis modification in ocular diseases.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
Open AccessLHPP Attenuates Lipid Dysfunction of Uveal Melanoma by Relieving the Histidine Phosphorylation of ACO2
Histidine phosphorylation, the neglected but vital phosphoproteome, is a reversible posttranslational modification catalyzed by histidine kinases and erased by phosphohistidine (pHis) phosphatases (e.g., LHPP). Traditional types of phosphorylation have been implicated with the deadliest adult ocular tumor uveal melanoma (UM), which is lipid metabolism dysfunction related. However, the role of histidine phosphorylation in UM remains unknown. Here, up-regulated histidine phosphorylation is associated with poor UM prognosis. Reversal of histidine phosphorylation by LHPP exerts therapeutic effects. Mechanistically, we identified LHPP as metabolically related protein with mitochondrial targeting sequence. LHPP interacts and reduces excessive histidine phosphorylation of mitochondrial aconitase ACO2 at H73 site, thus restoring ACO2 enzymatic activity and mitochondrial citrate transit in TCA cycle. Reduction of citrate accumulation attenuates overloaded lipid synthesis. Besides, genetic ablation of LHPP in mouse eye exhibits abnormal lipid metabolism. These findings illustrate the antagonistic roles of oncogenic histidine phosphorylation and therapeutic mitochondrial LHPP and provide metabolic insight of pHis modification in ocular diseases.
- 22 April 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 268, 131678
SUMOylation of GMFB regulates its stability and function in retinal pigment epithelial cells under hyperglycemia
- 22 April 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 268, 131678
SUMOylation of GMFB regulates its stability and function in retinal pigment epithelial cells under hyperglycemia
- 10 February 2023
- Published by Springer Nature in Oncogene
- Vol. 42 (14) , 1058-1071
Glucose-mediated N-glycosylation of RPTPα affects its subcellular localization and Src activation
Receptor-type protein tyrosine phosphatase α (RPTPα) is one of the typical PTPs that play indispensable roles in many cellular processes associated with cancers. It has been considered as the most powerful regulatory oncogene for Src activation, however it is unclear how its biological function is regulated by post-translational modifications. Here, we show that the extracellular segment of RPTPα is highly N-glycosylated precisely at N21, N36, N68, N80, N86, N104 and N124 sites. Such N-glycosylation modifications mediated by glucose concentration alter the subcellular localization of RPTPα from Golgi apparatus to plasma membrane, enhance the interaction of RPTPα with Src, which in turn enhances the activation of Src and ultimately promotes tumor development. Our results identified the N-glycosylation modifications of RPTPα, and linked it to glucose starvation and Src activation for promoting tumor development, which provides new evidence for the potential antitumor therapy.
- 10 February 2023
- Published by Springer Nature in Oncogene
- Vol. 42 (14) , 1058-1071
Glucose-mediated N-glycosylation of RPTPα affects its subcellular localization and Src activation
Receptor-type protein tyrosine phosphatase α (RPTPα) is one of the typical PTPs that play indispensable roles in many cellular processes associated with cancers. It has been considered as the most powerful regulatory oncogene for Src activation, however it is unclear how its biological function is regulated by post-translational modifications. Here, we show that the extracellular segment of RPTPα is highly N-glycosylated precisely at N21, N36, N68, N80, N86, N104 and N124 sites. Such N-glycosylation modifications mediated by glucose concentration alter the subcellular localization of RPTPα from Golgi apparatus to plasma membrane, enhance the interaction of RPTPα with Src, which in turn enhances the activation of Src and ultimately promotes tumor development. Our results identified the N-glycosylation modifications of RPTPα, and linked it to glucose starvation and Src activation for promoting tumor development, which provides new evidence for the potential antitumor therapy.
- 1 January 2020
- Published by Elsevier in Cancer Letters
- Vol. 469, 301-309
SUMOylation homeostasis in tumorigenesis
- 1 January 2020
- Published by Elsevier in Cancer Letters
- Vol. 469, 301-309
SUMOylation homeostasis in tumorigenesis